Cannabis vaping and mental health: The association of Δ‐9‐tetrahydrocannabinol and cannabidiol with anxiety and depressive symptoms—Findings from the United States National Youth Tobacco Survey (2021–2023)
Abstract
Background and aim: Cannabis use is associated with psychiatric comorbidities, and the use of elta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) produces different neurophysiological and pharmacological effects. This study estimated the strength of associations between vaping of THC and CBD with depressive and anxiety symptoms in adolescents. Design: Observational data were drawn from three years of the nationally representative US National Youth Tobacco Survey (2021–2023). The survey adopted a probabilistic stratified, three‐stage cluster design. Setting: The United States. Participants: A total of 69 899 adolescents aged 11 to 18, with 51.3% males. Measurements: CBD and THC cannabis vaping behaviours; Patient Health Questionnaire 2‐item and Generalised Anxiety Disorder 2‐item, which respectively assess depressive and anxiety symptoms. Logistics regression analyses were conducted after multiple imputation and adjusting for covariates. Findings: Relative to those who did not vape, adolescents who vaped THC only [adjusted odds ratio (aOR) = 1.40, 95% confidence interval (CI) = 1.20–1.64] or dual CBD/THC (aOR = 1.51, 95% CI = 1.22–1.86) were more likely to experience depressive symptoms; whereas those who vaped CBD only (aOR = 1.74, 95% CI = 1.24–2.46) or THC only (aOR = 1.18, 95% CI = 1.01–1.38) were more likely to experience anxiety symptoms. When the sample was restricted to adolescents who had vaped cannabis products, those who only vaped CBD had a higher likelihood of experiencing anxiety symptoms (aOR = 1.51, 95% CI = 1.05–2.17), relative to those who exclusively vaped THC. Conclusions: Among adolescents, Δ‐9‐tetrahydrocannabinol (THC) vaping and dual THC/cannabidiol vaping might be associated with an increased risk of experiencing depressive symptoms. In contrast, adolescents who vape cannabidiol may have a higher likelihood of experiencing anxiety symptoms.Keywords
This publication has 66 references indexed in Scilit:
- Cannabis-Derived Product Types, Flavors, and Compound Types From an E-Commerce WebsiteJAMA Network Open, 2024
- Prevalence and Factors Associated With Vaping Cannabidiol Among US AdolescentsJAMA Network Open, 2023
- Vaping of Cannabis, Cannabidiol, and Synthetic Cannabis Among US Sexual Minority YouthsJAMA Network Open, 2023
- Associations between cannabis use, cannabis use disorder, and mood disorders: longitudinal, genetic, and neurocognitive evidencePsychopharmacology, 2021
- Prevalence of Adolescent Cannabis VapingJAMA Pediatrics, 2021
- Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving PerformanceJAMA, 2020
- Association of High-Potency Cannabis Use With Mental Health and Substance Use in AdolescenceJAMA Psychiatry, 2020
- Self-reported Marijuana Use in Electronic Cigarettes Among US Youth, 2017 to 2018JAMA, 2020
- Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young AdulthoodJAMA Psychiatry, 2019
- Anxiogenic-like effects of chronic cannabidiol administration in ratsPsychopharmacology, 2011